SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-265360
Filing Date
2022-10-19
Accepted
2022-10-19 17:06:41
Documents
21
Period of Report
2022-10-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d382653d8k.htm   iXBRL 8-K 64354
2 EX-2.1 d382653dex21.htm EX-2.1 559425
3 EX-10.1 d382653dex101.htm EX-10.1 63322
4 EX-10.2 d382653dex102.htm EX-10.2 62847
5 EX-10.3 d382653dex103.htm EX-10.3 7276
6 EX-10.4 d382653dex104.htm EX-10.4 7313
7 EX-10.5 d382653dex105.htm EX-10.5 7470
8 EX-99.1 d382653dex991.htm EX-99.1 26964
9 EX-99.2 d382653dex992.htm EX-99.2 39213
13 GRAPHIC g382653dsp130.jpg GRAPHIC 4157
  Complete submission text file 0001193125-22-265360.txt   1173547

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA ayla-20221018.xsd EX-101.SCH 2871
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE ayla-20221018_lab.xml EX-101.LAB 18672
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ayla-20221018_pre.xml EX-101.PRE 11694
15 EXTRACTED XBRL INSTANCE DOCUMENT d382653d8k_htm.xml XML 3455
Mailing Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801
Business Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801 (857) 444-0553
Ayala Pharmaceuticals, Inc. (Filer) CIK: 0001797336 (see all company filings)

IRS No.: 823578375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39279 | Film No.: 221319177
SIC: 2836 Biological Products, (No Diagnostic Substances)